Synairgen (LON:SNG)‘s stock had its “corporate” rating reiterated by FinnCap in a research note issued to investors on Tuesday, November 21st.
Separately, N+1 Singer reissued an “under review” rating on shares of Synairgen in a research report on Wednesday, September 6th.
Synairgen (LON:SNG) remained flat at $GBX 10.75 ($0.14) during midday trading on Tuesday. 22,000 shares of the company traded hands, compared to its average volume of 64,351. Synairgen has a fifty-two week low of GBX 6.88 ($0.09) and a fifty-two week high of GBX 32 ($0.43).
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with MarketBeat.com's FREE daily email newsletter.